Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 1

2(40.0%)

Phase 2

1(20.0%)

5Total

N/A(2)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05265052Phase 2Not Yet Recruiting

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Role: lead

NCT05320809Phase 1Active Not Recruiting

Study of 3D189 in Patients With Hematologic Malignancies

Role: lead

NCT04584008Not ApplicableActive Not Recruiting

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics

Role: collaborator

NCT04941313Phase 1Completed

Phase 1 Study of 3D229 in Healthy Subjects

Role: lead

NCT05218759Not ApplicableUnknown

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Role: collaborator

NCT02715089Unknown

Precise Treatment in Hepatobiliary Cancers (PTHBC)

Role: collaborator

All 6 trials loaded